




The relative strengths and weaknesses of GYRE Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 98% points. The greatest weakness of GYRE Therapeutics INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 265%, being 27% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	96,066
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	28,899
Liabilities, Non-Current	1,319
Other Assets	2,184
Other Compr. Net Income	38
Other Expenses	0
Other Liabilities	0
Other Net Income	2,099
Other Revenues	0
Property and Equipment	304
Research and Development	43,859
Selling, General and Administrative Expense	13,418

Output Variable	Value in 1000 USD
Assets	98,554
Liabilities	30,218
Expenses	57,277
Revenues	0
Stockholders Equity	68,336
Net Income	-55,178
Comprehensive Net Income	-55,159
BaseVar	94,093
ECR before Limited Liability	146%
Economic Capital Ratio	265%